Company / R&D per Share
United Therapeutics R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$12.27
FY2025
5-year range
$7.16 / $12.27
FY2021-FY2025
Trend
+20.0%
vs FY2024
Sector context
#15 of 208
Health Care
What the data says
Among 208 Health Care companies, United Therapeutics is in the top 7% for r&d per share. R&D per Share has increased for 3 consecutive years, from $7.16 in FY2022 to $12.27 in FY2025.
Based on SEC 10-K filings.
12.27 in FY2025 with a 5-year CAGR of +8.5%. Top quartile in the Health Care sector.
Improved from $8.86 to $12.27 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +19.7%
- 5-Year CAGR
- +8.5%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 208This company $12.27 Sector average $28.82
▼
-57.4% below sector average
Key checks
Key Insights
- United Therapeutics's r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 20.0% year-over-year.
- Ranks #15 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.27 | +20.0% |
| FY2024 | $10.23 | +15.4% |
| FY2023 | $8.86 | +23.8% |
| FY2022 | $7.16 | -41.0% |
| FY2021 | $12.14 | +48.9% |
| FY2020 | $8.15 | -70.0% |
| FY2019 | $27.13 | +227.8% |
| FY2018 | $8.28 | +45.1% |
| FY2017 | $5.70 | +76.9% |
| FY2016 | $3.23 | -38.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026